About the Company
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $STML News
Menarini bags blood cancer drug with $677M Stemline acquisition
Italian drugmaker Menarini has agreed to buy Stemline Therapeutics, bolting on an already-approved drug for a rare form of haematological cancer and establishing a beachhead in the US. Privately ...
LCTX Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops ...
PTGX Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing ...
Aquestive Therapeutics, Inc. (AQST)
WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company ...
Revance Therapeutics, Inc. (RVNC)
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript February 29, 2024 Revance Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
Vertex to Pay $4.9 Billion for Kidney Disease Drug Developer
Vertex Pharmaceuticals Inc. agreed to buy Alpine Immune Sciences Inc. for a total equity value of about $4.9 billion, adding ...
Aclaris Therapeutics Inc ACRS
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Amicus Therapeutics Inc FOLD
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Fate Therapeutics, Inc.
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno ...
Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms ...
Vertex Pharma Obtains Exclusive License To TreeFrog's Cell Manufacturing Technology, C-Stem
Vertex Pharmaceuticals Inc. (VRTX) announced Tuesday that it has obtained an exclusive license from TreeFrog Therapeutics, a ...
Viking Therapeutics Inc (VKTX)
On Tuesday, Viking Therapeutics (NASDAQ:VKTX) saw its price target increased by an Oppenheimer analyst to $138 from the previous $116, while the stock's rating remains at... On Tuesday, Viking ...
Loading the latest forecasts...